NWS
DFTX

Newport Wealth Strategies’s Definium Therapeutics DFTX Stock Holding History

Newport Wealth Strategies’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$33K Buy
947
+67
+8% +$2.9K 0.02% 110
2021
Q2 		$46K Buy
+880
New +$46.2K 0.03% 112

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Newport Wealth Strategies's DFTX Position: Q3 2021 in Review

Newport Wealth Strategies increased its Definium Therapeutics (DFTX) stake by 7.6% in Q3 2021, buying an estimated $2.9K and bringing the position to 947 shares worth $33K. The position accounts for 0.02% of the portfolio, ranked #110.

Newport Wealth Strategies first reported a position in DFTX in Q2 2021 and has held it in 2 quarters since. The position peaked at $46K in Q2 2021. 174 funds tracked by Wall St. Rank hold DFTX as of Q3 2021.

  • Newport Wealth Strategies held 947 shares of Definium Therapeutics worth $33K as of Q3 2021.
  • Newport Wealth Strategies bought 67 Definium Therapeutics shares in Q3 2021, an estimated $2.9K.
  • Definium Therapeutics made up 0.02% of Newport Wealth Strategies's portfolio in Q3 2021, its #110 holding.
  • Newport Wealth Strategies first reported a position in Definium Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • Newport Wealth Strategies's Definium Therapeutics position peaked at $46K in Q2 2021.
  • 174 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2021.

Based on Newport Wealth Strategies's 13F filing for Q3 2021, filed 12 Nov 2021.